Jump to main content
Jump to site search

Issue 52, 2016, Issue in Progress
Previous Article Next Article

Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

Author affiliations

Abstract

Clinical application of vincristine in treatment of cancer is restricted because of its poor solubility and neuropathy. Targeted delivery of cytotoxic drugs could improve their therapeutic efficacy and reduce their severe side effects. Biocompatibility and high accumulation of human serum albumin nanoparticles (HSA) in tumors make this substance an ideal candidate for biomedical usage. Here, a Vincristine–HSA–Sgc8c aptamer (Apt) complex was designed and assessed for the treatment of Molt-4 cells (human acute lymphoblastic leukemia T-cell, target). Vincristine–HSA conjugate and Vincristine–HSA–Apt complex formations were analyzed by particle size analyzer, transmission electron microscopy (TEM) and gel retardation assay. Internalization of the Vincristine–HSA–FAM (3′-fluorescein)-labeled Apt complex into Molt-4 (target) and U266 cells (B lymphocyte human myeloma, nontarget) was monitored by confocal imaging and flow cytometry analysis. For cell viability (MTT assay), both cell lines were treated with vincristine, Vincristine–HSA conjugate, HSA–Apt conjugate and Vincristine–HSA–Apt complex. Vincristine was efficiently loaded (8.5%) into HSA. The results of confocal imaging and flow cytometry analysis indicated that the Vincristine–HSA–FAM-labeled Apt complex was effectively internalized into target cells (Molt-4) but not into nontarget cells (U266). The results of MTT assay also confirmed the internalization data. The Vincristine–HSA–Apt complex had less cytotoxicity in U266 cells compared to vincristine alone and Vincristine–HSA conjugate. In conclusion, the developed drug delivery system acquired properties of high drug loading, high cancer cell accumulation and cancer cell targeting.

Graphical abstract: Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

Back to tab navigation

Publication details

The article was received on 02 Apr 2016, accepted on 04 May 2016 and first published on 06 May 2016


Article type: Paper
DOI: 10.1039/C6RA08481H
RSC Adv., 2016,6, 46366-46371

  •   Request permissions

    Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

    S. M. Taghdisi, N. M. Danesh, M. Ramezani and K. Abnous, RSC Adv., 2016, 6, 46366
    DOI: 10.1039/C6RA08481H

Search articles by author

Spotlight

Advertisements